Alto Neuroscience
ANRO
110 hedge funds and large institutions have $602M invested in Alto Neuroscience in 2026 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 27 increasing their positions, 43 reducing their positions, and 10 closing their positions.
2,756% more call options, than puts
Call options by funds: $10.4M | Put options by funds: $364K
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
38% more capital invested
Capital invested by funds: $436M → $602M (+$167M)
13% more funds holding
Funds holding: 97 → 110 (+13)
5.17% more ownership
Funds ownership: 78.82% → 83.99% (+5.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
37% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSC
Spruce Street Capital
New York
|
+$20.4M |
| 2 |
CC
Commodore Capital
New York
|
+$16.7M |
| 3 |
AAA
Affinity Asset Advisors
New York
|
+$9.27M |
| 4 |
VA
VR Adviser
New York
|
+$9.27M |
| 5 |
Jennison Associates
New York
|
+$7.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.5M |
| 2 |
AC
Armistice Capital
New York
|
-$11.6M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$7.8M |
| 4 |
Alkeon Capital Management
New York
|
-$4.63M |
| 5 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$4.52M |
ANRO Hedge Fund Activity: Q1 2026 in Review
110 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Alto Neuroscience (ANRO) for Q1 2026, worth a combined $602M — up 38% from $436M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ANRO positions and 10 closed out — a net gain of 15 holders — while 27 added to existing stakes and 43 trimmed.
The largest buyer was Spruce Street Capital, adding an estimated $20.4M. The largest seller was Point72 Asset Management, cutting an estimated $20.5M.
- 110 institutional investors held Alto Neuroscience (ANRO) as of Q1 2026, up from 97 in Q4 2025.
- Funds reported $602M of Alto Neuroscience stock for Q1 2026, up 38% quarter-over-quarter.
- 25 funds opened new Alto Neuroscience positions in Q1 2026 and 10 closed out, a net change of +15 holders.
- The largest Alto Neuroscience buyer in Q1 2026 was Spruce Street Capital, an estimated $20.4M added.
- The largest Alto Neuroscience seller in Q1 2026 was Point72 Asset Management, an estimated $20.5M sold.
Based on aggregated 13F filings for Q1 2026.